Core Viewpoint - The establishment of a joint venture, Jindawei (Inner Mongolia) Nutritional Food Co., Ltd., between Jindawei Pharmaceutical and Aibede Life Science Research Institute aims to enhance product absorption efficiency and competitiveness in the global market [1] Group 1 - The joint venture is located in the industrial park of Tokto County, Hohhot City, Inner Mongolia [1] - The collaboration will leverage nanocrystal production technology for products such as Coenzyme Q10, Astaxanthin, Curcumin, and Quercetin [1] - The application of this technology is expected to significantly improve the absorption speed and efficiency of the company's related products [1]

Core Viewpoint - The article emphasizes the launch of a three-year "Weight Management Year" initiative by the National Health Commission to address the increasing issues of overweight and obesity in China, promoting scientific weight loss and healthy lifestyles [3][4]. Group 1: Current Situation of Overweight and Obesity - The report indicates that the overweight and obesity rates among Chinese youth aged 6-17 have reached 19%, while the adult population's rate stands at 50.7% [5]. - Over the past 15 years, the obesity rate among adolescents has surged by 12 times, with workplace-related obesity and elderly obesity becoming more prevalent [5]. - Chronic diseases related to obesity, such as hypertension, diabetes, and cardiovascular diseases, account for over 70% of the national disease burden, with direct medical expenses exceeding 240 billion yuan annually [5]. Group 2: Obesity Assessment Criteria - Obesity is primarily assessed using BMI and waist circumference metrics, with a normal BMI range defined as 18.5 to 23.9 [6]. - Waist circumference is a critical indicator of abdominal obesity, with men exceeding 90 cm and women exceeding 85 cm at risk [8]. - Other common obesity assessment indicators include body fat percentage and waist-to-hip ratio, with specific thresholds indicating obesity risk [9]. Group 3: Consequences of Obesity - Obesity is linked to increased body weight and is closely associated with blood sugar and lipid levels, leading to insulin resistance and elevated blood sugar, which can progress to diabetes [10]. - It is also a significant risk factor for dyslipidemia, with excess body fat leading to abnormal blood lipid levels [11]. - Regular monitoring of blood sugar and lipid levels is essential, even for individuals with a normal BMI, to ensure metabolic health [12]. Group 4: Multi-Dimensional Weight Management Strategies - Enhancing basal metabolic rate (BMR) through muscle gain and regular exercise is crucial for effective weight management [13]. - B vitamins play a vital role in energy metabolism, influencing both basal and activity metabolic rates, and their deficiency can lead to metabolic disorders [14]. - Reducing exposure to toxic elements and endocrine disruptors is important for maintaining metabolic balance and preventing obesity [15]. Group 5: Gut Health and Digestion - A healthy gut is essential for nutrient absorption and waste elimination, with gut microbiota playing a significant role in weight regulation [17]. - Hormonal balance, regulated by the endocrine system, is critical for metabolism and energy management, with disruptions potentially leading to obesity [17]. - A balanced diet, incorporating various nutrients, is fundamental for effective weight management and healthy weight loss [17].

Core Viewpoint - VIKPRO showcased its new product, the "Nurturing Ovarian Pill," at the Vitafoods Europe 2025 event, highlighting its commitment to women's health and innovative nutritional solutions [1][7]. Group 1: Product Launch and Market Position - VIKPRO received dual first-place market position certifications for Coenzyme Q10 and Quercetin from Euromonitor International, affirming its status as a leader in sales and product quality [3]. - The "Nurturing Ovarian Pill" is designed to enhance ovarian vitality through a three-dimensional targeting strategy, addressing cellular repair, energy revitalization, and hormonal balance for women over 35 [7][9]. Group 2: Scientific Collaboration and Innovation - VIKPRO has established a strategic partnership with Düsseldorf Medical University and appointed Prof. Dr. Nicole Teusch as the chief scientific advisor to enhance its research capabilities and product development [5]. - The company emphasizes a cell-level health approach, integrating advanced German technology to innovate and upgrade its product offerings [5][12]. Group 3: Consumer Engagement and Market Strategy - The new product has been well-received in the Chinese market during the Tmall 618 pre-sale, indicating strong consumer interest and positive feedback [10]. - VIKPRO aims to continue expanding in the European health market, focusing on consumer needs and collaborating with global partners to deliver high-quality health products [12].

Group 1: Investor Relations Activity Overview - The investor relations activity was conducted on May 15, 2025, at Chengdu Oukang Pharmaceutical Co., Ltd. [3] - Attendees included representatives from Kaiyuan Securities, Huayuan Securities, Zhongrui Huyin, and Luxin Chuangtou [3] - Company representatives included Chairman Zhao Zhuojun and CFO Cao Yongqiang [3] Group 2: Impact of Industry Trends - The overall price decline in the vitamin industry has limited impact on the company's product pricing, which is primarily influenced by raw material supply and market demand [5] - The company specializes in flavonoid products, a niche within the vitamin sector, using raw materials like bitter orange and sophora flower [5] Group 3: Production Capacity and Utilization - The new plant's production lines for bitter orange are expected to achieve over 50% capacity utilization by the end of 2025 [6] - The production lines for sophora flower are also projected to reach 50% capacity utilization by year-end 2025, with a focus on fine management and market expansion [6] Group 4: Market Expansion and Partnerships - The company has established strong partnerships in Japan for its sophora flower and bitter orange products, focusing on the food additive and health product markets [7] - Ongoing efforts are being made to deepen cooperation with clients and expand market influence in Japan [7] Group 5: Facility Upgrades and Compliance - Upgrades to the Diosmin and Rutin production lines have been completed, meeting both domestic and international GMP standards [8] - The upgraded lines have passed domestic GMP compliance checks and are in the process of obtaining EuGMP certification [8] Group 6: Financial Projections - The company anticipates a 160% increase in depreciation expenses for 2025 compared to 2024 due to the completion of investment projects [9] - Strategies will be implemented to enhance sales revenue to offset increased depreciation costs [9] Group 7: Profitability and Market Trends - The company's gross margin has declined due to production challenges and increased costs in Q1 2025, but is expected to recover as production lines stabilize [11] - The market for quercetin is projected to grow significantly due to rising health awareness and demand for natural ingredients, particularly in health supplements and functional foods [12]

Group 1: Investor Relations Activities - The company held a performance briefing for the 2024 annual report on April 29, 2025, via online communication [4] - Participants included the chairman, general manager, board secretary, financial officer, and sponsor representative [4] Group 2: Market Expansion and Product Certification - The company has obtained the EU export certification for its products, which requires compliance with the European Pharmacopoeia (CEP) and on-site inspections [5] - The company aims to enhance its competitiveness in the EU market by improving production quality and collaborating with EU clients [5] Group 3: Revenue Composition and Market Share - The company's revenue is primarily derived from pharmaceutical raw materials, food additives, cosmetics, and health products [6] - The European market accounts for approximately 40% of exports, while the US, Japan, Australia, and Canada account for about 60% [6] - The NHDC product has captured over 27% of the company's main business revenue in the domestic food additive market [6] Group 4: Growth Drivers and Strategic Focus - Future growth in the plant extract industry is driven by increasing consumer health awareness and advancements in extraction technology [8] - The company plans to deepen its focus on both domestic and international markets, particularly in food additives and pharmaceutical raw materials [9] Group 5: Financial Performance and Profit Margins - The company's revenue increased by 27.78% year-on-year in 2024, attributed to the successful implementation of its strategic plan [7] - The overall gross margin for products increased in 2024, but is expected to decline in 2025 due to rising costs and market competition [10] Group 6: Production and R&D Updates - The company is currently optimizing production processes and has completed 11 R&D projects in 2024 [15] - The new production lines are expected to be fully operational by mid-2025, which will enhance production capacity [14] Group 7: Market Trends and Future Outlook - The company anticipates a gradual recovery in gross margins as production lines stabilize and international trade conditions improve [12][13] - The market for Vitamin P products is expected to grow significantly due to rising health consciousness and expanding application areas [17]